Literature DB >> 16908925

Lipohypertrophy in acromegaly induced by the new growth hormone receptor antagonist pegvisomant.

Pietro Maffei, Chiara Martini, Claudio Pagano, Nicola Sicolo, Francesco Corbetti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16908925     DOI： 10.7326/0003-4819-145-4-200608150-00017

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN： 0003-4819            Impact factor:   25.391


× No keyword cloud information.
  16 in total

Review 1.  Acromegaly.

Authors:  Anat Ben-Shlomo; Shlomo Melmed
Journal:  Endocrinol Metab Clin North Am       Date:  2008-03       Impact factor: 4.741

Review 2.  Somatostatin analog and pegvisomant combination therapy for acromegaly.

Authors:  Sebastian J C Neggers; Aart Jan van der Lely
Journal:  Nat Rev Endocrinol       Date:  2009-10       Impact factor: 43.330

Review 3.  Pegvisomant in acromegaly: why, when, how.

Authors:  A Colao; G Arnaldi; P Beck-Peccoz; S Cannavò; R Cozzi; E degli Uberti; L De Marinis; E De Menis; D Ferone; V Gasco; A Giustina; S Grottoli; G Lombardi; P Maffei; E Martino; F Minuto; R Pivonello; E Ghigo
Journal:  J Endocrinol Invest       Date:  2007-09       Impact factor: 4.256

4.  Effect of rosiglitazone on serum IGF-I concentrations in uncontrolled acromegalic patients under conventional medical therapy: results from a pilot phase 2 study.

Authors:  F Bogazzi; G Rossi; M Lombardi; F Raggi; C Urbani; C Sardella; C Cosci; E Martino
Journal:  J Endocrinol Invest       Date:  2010-07-29       Impact factor: 4.256

5.  Does pegvisomant treatment expertise improve control of resistant acromegaly? The Italian ACROSTUDY experience.

Authors:  S Cannavo; F Bogazzi; A Colao; L De Marinis; P Maffei; R Gomez; E Graziano; M Monterubbianesi; S Grottoli
Journal:  J Endocrinol Invest       Date:  2015-04-28       Impact factor: 4.256

Review 6.  Lipodystrophy during pegvisomant therapy: a case report and review of the literature.

Authors:  D Buyuktas; O Celik; F Kantarci; P Kadioglu
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

7.  Growth hormone receptor polymorphism and the effects of pegvisomant in acromegaly.

Authors:  Antonio Bianchi; Gherardo Mazziotti; Laura Tilaro; Vincenzo Cimino; Flora Veltri; Eleonora Gaetani; Giovanni Pecorini; Alfredo Pontecorvi; Andrea Giustina; Laura De Marinis
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

8.  Self-limited acute hepatotoxicity caused by pegvisomant.

Authors:  A Soto Moreno; R Guerrero Vázquez; E Venegas Moreno; S Palma Milla; J P Castaño; A Leal Cerro
Journal:  Pituitary       Date:  2011-12       Impact factor: 4.107

9.  Clinical and radiological evidence of the recurrence of reversible pegvisomant-related lipohypertrophy at the new site of injection in two women with acromegaly: a case series.

Authors:  Vincenzo Rochira; Lucia Zirilli; Chiara Diazzi; Stefania Romano; Cesare Carani
Journal:  J Med Case Rep       Date:  2012-01-10

Review 10.  Medical management of functioning pituitary adenoma: an update.

Authors:  Yutaka Oki
Journal:  Neurol Med Chir (Tokyo)       Date:  2014-11-29       Impact factor: 1.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.